💡☝🏽Broad panel-based NGS genomic testing🧬for non-metastatic #ColorectalCancer should be in the guidelines: We have ▪️PIK3CA consider testing statement➡️Aspirin💊 Don’t miss your ▪️MSS POL-E patient🟰immunotherapy💉 BRAF, HER2, MSI, & 🔜KRAS for adjuvant➕trials. OncoAlert

📗Management of HCC CA: A Cancer Journal for Clinicians ✅ A review from diagnosis to treatments 👉doi.org/10.3322/caac.7… OncoAlert #cancer #Oncology #MedX #liver

🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯 Years of grit & belief led us here 🥹 Endless thanks to Exelixis⁩ for the trust & Dr. Hecht for leading this global win with me! 🎉 ⁦UPMC Hillman Cancer Center⁩ ir.exelixis.com/news-releases/…

Part 1: Consensus guideline for the management of patients with appendiceal tumors: Appendiceal tumors without peritoneal involvement - Godfrey - 2025 - Cancer - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Deepa Magge Kiran Turaga Ardaman Shergill Mike Foote ACS Journal Cancer

Here we propose an algorithmic approach to treatment based on expressed biomarkers and considering magnitude of benefit and anticipated side effects

Zanidatamab plus chemotherapy as first-line treatment for HER2-positive GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎single-arm, phs 2 👉ORR 76·2% 👉mPFS 12·5 mo 👉mOS 36·5 mo 🧐Looks promising, now combo w/ ICI, phs-3 awaited ESMO - Eur. Oncology

Daraxonrasib Earns U.S. FDA Breakthrough Status in #PancreaticCancer #ESMOGI25 targetedonc.com/view/daraxonra…

Omitting bolus 5-FU in GI cancer chemo: a meta-analysis 🔬 pubmed.ncbi.nlm.nih.gov/40590359/ In 12,698 pts, skipping bolus 5-FU ➡️ ↓ grade 3–4 neutropenia (🧪 OR 0.46) & thrombocytopenia (🩸 OR 0.53) without compromising PFS or OS ✅ 💪Safer option, same efficacy.

Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice OncoAlert ASCO ascopubs.org/doi/10.1200/OP… Practical tips!!

Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer ESMO Gastrointestinal Oncology doi.org/10.1016/j.esmo… 🔎 65 zolbetuximab pts 👉53.3% converted to CLDN18.2-negative 🧐low level expression often preserved, opportunity for

New ADC data published in Nature Medicine by Scott Kopetz & colleagues: Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial nature.com/articles/s4159… 90% of #ColorectalCancer cases over express cell surface CEACAM5

More disappointing news in #HCC: Adjuvant pembrolizumab failed to beat surveillance in the global P3 #KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after #IMbrave050

#ScienceSaturday ❓ Why do some gastrointestinal cancers become resistant to KRAS-targeted therapies? ➡️ A new study in Cell Reports Medicine shows that cancer cells can bypass KRAS inhibition by switching on a protein called syndecan-1 (SDC1), which helps them keep growing.

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: an individual patient data-based pooled analysis of randomized trials ejcancer.com/article/S0959-…

Great progress for patients with CRC with BRAF V600E. Awaiting SWOG 2107 (NCT05308446) in MSS CRC, SEAMARK (NCT05217446) in MSI-H cRC and other trials.